This is a pilot, single center study. Patients with histologically proven, Stage III/IV NSCLC will be eligible. Patients will be stratified by central or peripheral location of the tumor. All patients will receive TEMLA to remove the mediastinal nodes, followed by a single fraction of SBRT delivering 30 Gy to the primary tumor and 10 Gy to the mediastinal lymph node beds (if possible on TEMLA), with or without minimally invasive surgery. Following radiation therapy, chemotherapy, at the discretion of the medical oncologist, may be initiated at any time after 2 weeks.